Las respuestas del presor a los fármacos bloqueadores beta-adrenérgicos.

Long-term treatment of hypertension with labetalol.

British journal of clinical pharmacology·2015

An Examination of Some Factors which Influence the Stability of in Vitro Platelet Responses.

Platelets·2010

Beta-adrenergic blocking drugs in the treatment of hypertension.

Blood pressure·2002

I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.

Drugs & aging·2000

New approaches to the uses of beta blocking drugs in hypertension.

Journal of human hypertension·2000

Moxonidine: a new antiadrenergic antihypertensive agent.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension·1999

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Intravenous Low-dose Buprenorphine for Acute Pain Management in the Emergency Department: A Case Series.

Clinical practice and cases in emergency medicine·2026

Comparative bioavailability of three benznidazole formulations in healthy individuals: a randomised study.

Memorias do Instituto Oswaldo Cruz·2026

A Regulatory-Ready Bayesian Evidence Framework across Clinical Development and Pharmacovigilance: Practical Expectations from FDA, EMA, and ICH Guidance.

Therapeutic innovation & regulatory science·2026

Patient Access to Buprenorphine at Community Pharmacies: A Scoping Review of Audit Studies.

Journal of addiction medicine·2026

Immunomodulatory Activity of Phenylephrine on LPS Stimulated Macrophages.

Immunopharmacology and immunotoxicology·2026

Postoperative Mortality Following Extended-Release Buprenorphine, Carprofen, and Bupivacaine Administration in Male ACI Rats (Rattus norvegicus).

Journal of the American Association for Laboratory Animal Science : JAALAS·2026

Videos de Experimentos Relacionados

Las respuestas del presor a los fármacos bloqueadores beta-adrenérgicos

Videos de Conceptos Relacionados

Long-term treatment of hypertension with labetalol.

An Examination of Some Factors which Influence the Stability of in Vitro Platelet Responses.

Beta-adrenergic blocking drugs in the treatment of hypertension.

I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.

New approaches to the uses of beta blocking drugs in hypertension.

Moxonidine: a new antiadrenergic antihypertensive agent.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Intravenous Low-dose Buprenorphine for Acute Pain Management in the Emergency Department: A Case Series.

Comparative bioavailability of three benznidazole formulations in healthy individuals: a randomised study.

A Regulatory-Ready Bayesian Evidence Framework across Clinical Development and Pharmacovigilance: Practical Expectations from FDA, EMA, and ICH Guidance.

Patient Access to Buprenorphine at Community Pharmacies: A Scoping Review of Audit Studies.

Immunomodulatory Activity of Phenylephrine on LPS Stimulated Macrophages.

Postoperative Mortality Following Extended-Release Buprenorphine, Carprofen, and Bupivacaine Administration in Male ACI Rats (Rattus norvegicus).

Videos de Experimentos Relacionados

Las respuestas del presor a los fármacos bloqueadores beta-adrenérgicos

Videos de Conceptos Relacionados

Artículos Relacionados